- Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityWith PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.BioSpace · 3d ago↗ source
- Indian generic drugmaker gets FDA warning over clinical study consentIndian generic drugmaker Alembic Pharmaceuticals has been hit with an FDA warning letter after failing to get informed consent from patients for a clinical study. In a breakaway from typical FDA…Endpoints · 3d ago↗ source
- Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challengeA group of 61 biopharma companies, executives and investors has filed an amicus brief in support of the FDA in an ongoing case brought by Louisiana meant to remove access to the abortion pill mifep…